FAQs

Key share figures

STADA’s market capitalization at year-end 2010 was EUR 1.494 billion. At the previous year end it had been EUR 1.424 billion. Based on Deutsche Börse AG’s index system, which only considers free float, STADA, in terms of market capitalization, occupied position 22 in the MDAX^® in 2010. STADA had occupied position 15 in this category in the previous year.

Click here for the current market capitalization!

Below you will find an overview of the key figures for the STADA share of the first nine months of 2011 and of the financial year 2010. The stock statistics for the last five financial years are presented on the lower table.

The deduction of such effects which have an impact on the presentation of STADA’s earnings situation and the derived key figures aims at improving the comparability of key figures with previous years. To achieve this, STADA uses adjusted key figures, which, as so called pro forma figures, are not governed by the accounting requirements in accordance with IFRS. As other companies may not calculate the pro forma figures presented by STADA in the same way, STADA’s pro forma figures are only comparable with similarly designated disclosures by other companies to a limited extent.

1)	Adjusted for one-time special effects as well as non-operational effects from currency influences and interest rate hedge transactions in 2010 and 2009.

1)	The accounting treatment of shareholdings in BIOCEUTICALS Arzneimittel AG was changed retroactively for the years 2007 to 2001. For reasons of the practicability caveat as specified under IAS 8.43 ff., the comparison figures and the key figures for the 2006 to 2001 period were not adapted. Therefore, disclosures made in the Annual Report 2010 for financial years 2006 and before do not include the recognition of BIOCEUTICALS Arzneimittel AG as an associated company under the equity method.
2)	In accordance with IAS 33.10.
3)	Adjustment for the one-time special effects as well as effects from currency influences and interest rate hedge transactions respectively incurred.
4)	In accordance with IAS 33.31.